#ibdsky
LightNews LightNews
gastrotoday.bsky.social
According to a retrospective cohort study by Elizabeth Spencer at Mount Sinai, #upadacitinib can be considered an effective maintenance treatment for pediatric patients with refractory #CrohnDisease.
#PediatricCrohnsDisease #PediatricIBD #IBDSky #GISky

www.docwirenews.com/post/real-wo...
Upadacitinib Maintenance for Pediatric CD | Gastro Today
Real-world data showed that upadacitinib is effective maintenance therapy for pediatric Crohn’s disease.
www.docwirenews.com
October 1, 2026 at 1:28 AM
gastrotoday.bsky.social
Family history of #ColorectalCancer increased the risk of #CRC similarly between patients with #IBD and the general population. Those with multiple relatives with CRC showed the highest increase in CRC risk. #IBDSky #GISky #GIOnc

www.docwirenews.com/post/family-...
How Does Family History of CRC Impact Risk for Patients With IBD? | Gastro Today
In a cohort study, patients with IBD and multiple family members with CRC were found to have the most increased risk of CRC.
www.docwirenews.com
September 19, 2026 at 1:32 AM
lancetgastrohep.bsky.social
🆕Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial

www.thelancet.com/journals/lan...

#GastroSky #IBDSky #MedSky
Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial
Early top-down anti-TNF treatment from diagnosis was associated with improved long-term outcomes at 5 years compared with step-up treatment and is suggestive of a disease-modifying effect in Crohn's disease.
www.thelancet.com
September 11, 2026 at 9:12 AM
gastrotoday.bsky.social
Is heat-not-burn #tobacco safer in #CrohnsDisease? A retrospective study found the use of #HNBT products was associated with increased risk of postoperative endoscopic recurrence of Crohn’s disease when compared with nonsmoking.
#GI #IBDSky

www.docwirenews.com/post/impact-...
Is Heat-Not-Burn Tobacco Safer in Crohn’s Disease? | Docwire News
According to a retrospective study, the use of heat-not-burn tobacco products was associated with increased risk of postoperative endoscopic recurrence of Crohn’s disease.
www.docwirenews.com
September 10, 2026 at 1:28 AM
gastrotoday.bsky.social
A meta-analysis and systemic review from @dranuraagj.bsky.social found JAK inhibitors to be "promising and effective options" for patients with acute severe #UlcerativeColitis as adjunct therapy to corticosteroids and rescue therapy. #ASUC #GISky #IBDSky

www.docwirenews.com/post/jak-inh...
JAK Inhibitors Promising for ASUC Management | Docwire News
A systematic review and meta-analysis found Janus kinase (JAK) inhibitors safe and effective for patients with acute severe ulcerative colitis.
www.docwirenews.com
September 5, 2026 at 1:32 AM
gastrotoday.bsky.social
Patients with #InflammatoryBowelDisease have an increased risk of psychiatric disorder from 2-3 years before diagnosis through 10 years after, highlighting the need for integration of psych. care into #IBD management. #GISky #IBDSky

🌟 Read the full article:
www.docwirenews.com/post/inflamm...
When Are Psychiatric Comorbidities in IBD Most Likely to Occur? | Docwire News
A cohort study of Swedish patients with inflammatory bowel disease found an increased risk of any psychiatric disorder from 2 to 3 years before diagnosis through 10 years after.
www.docwirenews.com
August 29, 2026 at 1:32 AM
lancetgastrohep.bsky.social
New Review - The trajectory of inflammatory bowel disease in east and southeast Asia: transitioning from acceleration in incidence to compounding prevalence

www.thelancet.com/journals/lan...

#GastroSky #IBDSky #MedSky
The trajectory of inflammatory bowel disease in east and southeast Asia: transitioning from acceleration in incidence to compounding prevalence
The epidemiology of inflammatory bowel disease (IBD) progresses through four stages: emergence (stage 1), acceleration in incidence (stage 2), compounding prevalence (stage 3), and prevalence equilibr...
www.thelancet.com
August 13, 2026 at 7:41 AM
gastrotoday.bsky.social
Adam Faye, MD, of NYU Langone Health, discusses the safety of #guselkumab among older patients with immune-mediated inflammatory diseases, such as #InflammatoryBowelDisease, #Psoriasis, and #PsoriaticArthritis. #IBDSky #GISky

📹 Watch the full interview here:
www.docwirenews.com/post/the-imp...
Balancing Disease Control and Safety for Older Adults With IBD | Docwire News
Adam Faye, MD, shares results from a study evaluating the safety of guselkumab among older populations of patients with immune-mediated inflammatory diseases.
www.docwirenews.com
August 6, 2026 at 12:28 AM
gastrotoday.bsky.social
Jeffrey Hyams, MD, discusses #ustekinumab for pediatric patients with #UlcerativeColitis who had conventional therapies. With the UNIFI JR results, ustekinumab may be "a very attractive therapy" for these patients. #GISky #IBDSky

📹 Watch the full interview here:
www.docwirenews.com/post/ustekin...
Ustekinumab May Fill Unmet Need for Pediatric Ulcerative Colitis | Docwire News
Jeffrey Hyams, MD, shares results from the UNIFI JR trial, evaluating ustekinumab for pediatric patients with ulcerative colitis who had received conventional therapies.
www.docwirenews.com
July 27, 2026 at 10:02 PM
gastrotoday.bsky.social
Corey Siegel, MD, from @dartmouthhealth.bsky.social, discusses the #RADIUSProgram which pairs a large specialty care center with small community-based practices to ensure no #IBD patient falls through the cracks. #GISky #IBDSky

📹 Watch the full interview here:
www.docwirenews.com/post/expandi...
Bringing IBD Specialty Care to Rural Regions | Docwire News
Corey Siegel, MD, discusses the RADIUS program, which pairs larger specialty centers with smaller rural practices to jointly oversee the care of patients with IBD.
www.docwirenews.com
July 21, 2026 at 12:27 AM
lancetgastrohep.bsky.social
🆕Results from RELIEVE UCCD - efficacy and safety of duvakitug in patients with Crohn's disease or ulcerative colitis

UC - www.thelancet.com/journals/lan...

CD - www.thelancet.com/journals/lan...

#GastroSky #MedSky #IBDSky
Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial
Duvakitug showed significant evidence for clinical remission versus placebo, with no safety concerns identified, in patients with moderately to severely active ulcerative colitis.
www.thelancet.com
July 17, 2026 at 5:20 AM
gastrotoday.bsky.social
Maarten Pruijt, MD, from Amsterdam University Medical Center, shares data on #IntestinalUltrasound and #FecalCalprotectin as a predictor of remission after ileocecal resection for #CrohnsDisease. #GISky #IBDSky

📹 Watch the full interview here:
www.docwirenews.com/post/non-inv...
Intestinal Ultrasound Plus Fecal Calprotectin Predicts Crohn’s Recurrence | Docwire News
Maarten Pruijt, MD, shares results from the INSIGHT study, evaluating intestinal ultrasound and fecal calprotectin to predict 6-month remission after ileocecal resection for CD.
www.docwirenews.com
July 2, 2026 at 12:28 AM
gastrotoday.bsky.social
Don't miss our interview with Edward Loftus, Jr, MD, of @mayoclinic.org, shares insights on the anti–IL-23 targeted oral peptide, #icotrokinra, in #UlcerativeColitis. #IBDSky #GISky

📹 Check out the full interview:
www.docwirenews.com/post/icotrok...
June 27, 2026 at 1:32 AM
lancetgastrohep.bsky.social
🆕 HLA-DRB1*01:03 in patients with inflammatory bowel disease: a genotype–phenotype association study

www.thelancet.com/journals/lan...

#IBDSky #GastroSky #MedSky
June 16, 2026 at 5:54 AM
gastrotoday.bsky.social
Christopher Ma, MD, of University of Calgary, shares results from the phase 2 ARTEMIS-UC trial, evaluating #tulisokibart for patients with moderately to severely active #UlcerativeColitis. #GISky #IBDSky

📹 Watch the full interview here:
www.docwirenews.com/post/tulisok...
Sustained Results With Tulisokibart for UC | Docwire News
Christopher Ma, MD, shares results from the phase 2 ARTEMIS-UC trial, evaluating tulisokibart, a TL1A monoclonal antibody, for moderately to severely active ulcerative colitis.
www.docwirenews.com
June 12, 2026 at 10:32 PM
gastrotoday.bsky.social
Uma Mahadevan, MD, from @ucsfhealth.bsky.social, discusses the delicate balance between drug safety and disease control for pregnant patients taking #JAKInhibitors for #IBD.

#GISky #PregnancyCare #IBDSky
📹 Watch the full interview:
www.docwirenews.com/post/birth-d...
Balancing Drug Safety and Disease Control in Pregnant Patients With IBD | Docwire News
Uma Mahadevan, MD, shares data on the risk for birth defects when JAK inhibitors are used during pregnancy for patients with inflammatory bowel disease.
www.docwirenews.com
June 9, 2026 at 12:27 AM
vomitodiarreia.bsky.social
ja caguei 4x hj #ibdsky
June 1, 2026 at 1:41 PM
gastrotoday.bsky.social
Stephen Hanauer, MD, from @feinberg.northwestern.edu, shares his Big 3 Takeaways for #IBD from #DDW2026: early effective treatment, the shift toward oral agents, and combination therapies. #GISky #IBDSky

📹 Don't miss the full interview:
www.docwirenews.com/post/digesti...
DDW 2026: 3 Big IBD Takeaways | Docwire News
Stephen Hanauer, MD, shares three main takeaways in inflammatory bowel disease from this year’s Digestive Disease Week.
www.docwirenews.com
May 25, 2026 at 9:27 PM
gastrotoday.bsky.social
We spoke with Nurulamin Noor, of@cuh.nhs.uk, at #DDW2026 about the PROFILE study, which found that early effective top-down therapy from the point of diagnosis appears to modify the course of #CrohnsDisease. #GISky #IBDSky

📹 Watch the full interview here:
www.docwirenews.com/post/earlier...
“Top-Down” Therapy for Crohn’s Disease | Docwire News
Nurulamin Noor, MD, PhD, discusses 4-year data from the PROFILE study, evaluating “top-down” therapy for patients with Crohn’s disease, as compared with the “step-up" approach.
www.docwirenews.com
May 22, 2026 at 10:32 PM
lancetgastrohep.bsky.social
New - Intestinal ultrasound to detect postoperative recurrence in patients with Crohn's disease: an international, multidisciplinary, RAND/UCLA appropriateness method study

www.thelancet.com/journals/lan...

#GastroSky #MedSky #IBDSky
May 21, 2026 at 9:10 AM
lancetgastrohep.bsky.social
🆕Viewpoint - Breaking the therapeutic ceiling in inflammatory bowel disease: myth or reality?

www.thelancet.com/journals/lan...

#GastroSky #MedSky #IBDSky
Breaking the therapeutic ceiling in inflammatory bowel disease: myth or reality?
Despite an expanding therapeutic armamentarium, remission rates in inflammatory bowel disease (IBD) appear to plateau at 30–50% after 1 year of treatment, leading to the concept of a therapeutic ceili...
www.thelancet.com
May 15, 2026 at 10:33 AM
gastrotoday.bsky.social
Subcutaneous #infliximab maintenance demonstrated consistent clinical and endoscopic efficacy across #CrohnsDisease locations.

Read more insights on #LIBERTYCD trial from Dr Colombel, of Icahn School of Medicine. #GISky #IBDSky

www.docwirenews.com/post/subcuta...
Subcutaneous Infliximab for CD by Location | Docwire News
Subcutaneous infliximab in maintenance showed consistent clinical, endoscopic efficacy across Crohn’s disease locations, including the terminal ileum.
www.docwirenews.com
April 23, 2026 at 9:41 PM
gastrotoday.bsky.social
The risk for mild infections, particularly viral infections, was found to increase with use of #thiopurines to treat patients with #InflammatoryBowelDisease; however, the risk for moderate-to-severe infections was not increased. #IBDSky #GISky

www.docwirenews.com/post/thiopur...
Thiopurines and Infection in IBD | Docwire News
Thiopurine use for IBD was associated with an increased risk for mild infections.
www.docwirenews.com
April 17, 2026 at 12:55 AM
gastrotoday.bsky.social
Professor Laurent Peyrin-Biroulet discusses a study evaluating use of the Iterative Health site network to improve enrollment for #InflammatoryBowelDisease trials. #IBDSky #GISky
📹 Watch the full interview at the link!

www.docwirenews.com/post/improvi...
Site Network for IBD Trials | Docwire News
Laurent Peyrin-Biroulet, MD, PhD, describes the results of a study evaluating use of a site network to improve enrollment for IBD trials.
www.docwirenews.com
March 26, 2026 at 12:28 AM
gastrotoday.bsky.social
In a large real-world study, more than 60% of patients with #CrohnsDisease treated with #risankizumab achieved steroid-free clinical remission by week 12, and through 1 year of treatment.
#Gastroenterology #GISky #inflammatoryBowelDisease #IBDSky
Risankizumab for Heavily Pretreated CD | Docwire News
Real-world data showed 60% of patients with heavily pretreated Crohn’s disease who received risankizumab achieved steroid-free clinical remission by week 12.
www.docwirenews.com
March 10, 2026 at 12:27 AM